Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy

Androgen deprivation therapy (ADT), which pharmacologically or surgically suppresses androgen activity, is a key treatment for prostate cancer (PCa).1 However, it is associated with increased cardiovascular risks, including elevated risks of cardiovascular mortality, myocardial infarction and stroke.2, 3 Nonetheless, prior studies have focussed on the first occurrence of adverse cardiovascular events,2, 4, 5 and the burden of cardiovascular hospitalizations in patients with PCa receiving ADT has remained unexplored. Similarly, the long-term burden of cardiovascular mortality amongst ADT users has been underexplored.6, 7 Given the adverse cardiovascular effects of ADT, it is important to better understand the long-term burden of cardiovascular mortality and hospitalizations in these patients. Henceforth, this study aimed to describe the long-term burden of cardiovascular mortality and hospitalizations in patients with PCa receiving ADT.